Breast Cancer/canceronco.com
Jan 20, 2025, 13:55
Elisabetta Bonzano: Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges
Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, posted on X about recent paper by I. Schlam et al., titled “Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges” published on Science Direct.
Authors: I. Schlam, S. Loi, R. Salgado, S.M. Swain.
“Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges.
- sTILs represent an accessible and highly reproducible biomarker.
- Higher quantities of sTILs are associated with higher rates of pCR in some patients with HER2-positive breast cancer.
- TILs serve as a positive prognostic indicator of recurrence-free survival in early HER2-positive disease.
- In metastatic disease, higher sTILs are a positive prognostic indicator for longer PFS.
- The widespread adoption of sTILs in clinical practice requires additional research.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 20, 2025, 13:55
Jan 20, 2025, 13:55
Jan 20, 2025, 13:55
Jan 20, 2025, 13:55
Jan 20, 2025, 13:55
Jan 20, 2025, 13:49
Jan 20, 2025, 13:46
Jan 20, 2025, 13:36